• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Value-based payment for high-cost treatments in Singapore: a qualitative study of stakeholders' perspectives.新加坡高成本治疗的基于价值的支付:利益相关者观点的定性研究。
Int J Technol Assess Health Care. 2024 Apr 17;40(1):e22. doi: 10.1017/S0266462324000217.
2
Conditional Financing of Drugs in the Netherlands: Past, Present, and Future-Results From Stakeholder Interviews.荷兰药品有条件融资:过去、现在和未来——利益相关者访谈结果。
Value Health. 2019 Apr;22(4):399-407. doi: 10.1016/j.jval.2018.11.016.
3
Use of real-world evidence in cancer drug funding decisions in Canada: a qualitative study of stakeholders' perspectives.加拿大癌症药物资助决策中真实世界证据的应用:对利益相关者观点的定性研究
CMAJ Open. 2020 Nov 24;8(4):E772-E778. doi: 10.9778/cmajo.20200118. Print 2020 Oct-Dec.
4
Healthcare stakeholders' perceptions and experiences of factors affecting the implementation of critical care telemedicine (CCT): qualitative evidence synthesis.医疗保健利益相关者对影响重症监护远程医疗(CCT)实施因素的看法和经验:定性证据综合分析。
Cochrane Database Syst Rev. 2021 Feb 18;2(2):CD012876. doi: 10.1002/14651858.CD012876.pub2.
5
Information sharing across institutions: Practices and barriers during public health emergencies in Ethiopia.信息在机构间的共享:埃塞俄比亚公共卫生突发事件期间的实践和障碍。
Int J Med Inform. 2024 Jun;186:105439. doi: 10.1016/j.ijmedinf.2024.105439. Epub 2024 Mar 30.
6
Multiple stakeholders' perspectives on patient and public involvement in community mental health services research: A qualitative analysis.多利益相关者对社区心理健康服务研究中患者和公众参与的观点:定性分析。
Health Expect. 2022 Aug;25(4):1844-1860. doi: 10.1111/hex.13529. Epub 2022 Jun 3.
7
Regulatory, Policy, and Operational Considerations for Outcomes-Based Risk-Sharing Agreements in the U.S. Market: Opportunities for Reform.基于结果的风险分担协议在美国市场的监管、政策和运营考虑因素:改革机遇。
J Manag Care Spec Pharm. 2019 Nov;25(11):1174-1181. doi: 10.18553/jmcp.2019.19167. Epub 2019 Sep 19.
8
Performance-based pharmacy payment models: key components and critical implementation considerations for successful uptake and integration.基于绩效的药房支付模式:成功采用和整合的关键组成部分和关键实施注意事项。
J Manag Care Spec Pharm. 2021 Nov;27(11):1568-1578. doi: 10.18553/jmcp.2021.27.11.1568.
9
Prescription drug monitoring program in Australia: a qualitative study of stakeholders' experiences and perceptions of a state-wide implementation.澳大利亚的处方药物监测项目:对利益相关者在全州范围内实施该项目的经验和看法的定性研究。
BMC Health Serv Res. 2024 Sep 29;24(1):1147. doi: 10.1186/s12913-024-11614-8.
10
Private sector risk-sharing agreements in the United States: trends, barriers, and prospects.美国私营部门风险分担协议:趋势、障碍与前景
Am J Manag Care. 2015 Sep;21(9):632-40.

引用本文的文献

1
Modeling First-Line Daratumumab Use for Newly Diagnosed, Transplant-Ineligible, Multiple Myeloma: A Cost-Effectiveness and Risk Analysis for Healthcare Payers.达雷妥尤单抗用于新诊断的、不符合移植条件的多发性骨髓瘤一线治疗的建模:针对医疗保健支付方的成本效益和风险分析
Pharmacoecon Open. 2024 Sep;8(5):651-664. doi: 10.1007/s41669-024-00503-9. Epub 2024 Jun 20.

本文引用的文献

1
Implementing outcomes-based risk-sharing agreements: an integrative review of applications in blood cancer in the UK and beyond.实施基于结果的风险分担协议:对英国及其他地区血液癌症应用的综合综述。
Expert Rev Pharmacoecon Outcomes Res. 2023 Jul-Dec;23(8):879-889. doi: 10.1080/14737167.2023.2240515. Epub 2023 Jul 27.
2
Sample sizes for saturation in qualitative research: A systematic review of empirical tests.定性研究中饱和度的样本量:实证检验的系统综述。
Soc Sci Med. 2022 Jan;292:114523. doi: 10.1016/j.socscimed.2021.114523. Epub 2021 Nov 2.
3
Characterization of the Pharmaceutical Risk-Sharing Arrangement Process in Catalonia.加泰罗尼亚药品风险共担安排流程的特征描述。
Pharmacoeconomics. 2021 Sep;39(9):973-982. doi: 10.1007/s40273-021-01046-1. Epub 2021 Jun 10.
4
Integrative Review of Managed Entry Agreements: Chances and Limitations.综合管理准入协议审查:机遇与限制。
Pharmacoeconomics. 2020 Nov;38(11):1165-1185. doi: 10.1007/s40273-020-00943-1.
5
The high cost of prescription drugs: causes and solutions.处方药的高昂成本:成因与解决方案。
Blood Cancer J. 2020 Jun 23;10(6):71. doi: 10.1038/s41408-020-0338-x.
6
The new definition of health technology assessment: A milestone in international collaboration.新的健康技术评估定义:国际合作的里程碑。
Int J Technol Assess Health Care. 2020 Jun;36(3):187-190. doi: 10.1017/S0266462320000215. Epub 2020 May 13.
7
Risk sharing in managed entry agreements-A review of the Swedish experience.管理准入协议中的风险分担-瑞典经验回顾。
Health Policy. 2020 Apr;124(4):404-410. doi: 10.1016/j.healthpol.2020.02.002. Epub 2020 Feb 18.
8
Development and Validation of the TRansparent Uncertainty ASsessmenT (TRUST) Tool for Assessing Uncertainties in Health Economic Decision Models.健康经济决策模型不确定性透明评估工具(TRUST)的开发与验证。
Pharmacoeconomics. 2020 Feb;38(2):205-216. doi: 10.1007/s40273-019-00855-9.
9
Grounded theory research: A design framework for novice researchers.扎根理论研究:新手研究者的设计框架。
SAGE Open Med. 2019 Jan 2;7:2050312118822927. doi: 10.1177/2050312118822927. eCollection 2019.
10
Health Technology Assessment and Its Use in Drug Policies: Singapore.卫生技术评估及其在药物政策中的应用:新加坡
Value Health Reg Issues. 2019 May;18:176-183. doi: 10.1016/j.vhri.2018.03.007. Epub 2018 Jun 25.

新加坡高成本治疗的基于价值的支付:利益相关者观点的定性研究。

Value-based payment for high-cost treatments in Singapore: a qualitative study of stakeholders' perspectives.

机构信息

Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore.

出版信息

Int J Technol Assess Health Care. 2024 Apr 17;40(1):e22. doi: 10.1017/S0266462324000217.

DOI:10.1017/S0266462324000217
PMID:38629196
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11569909/
Abstract

OBJECTIVES

The rising costs of drugs have necessitated the exploration of innovative payment methods in healthcare systems. Risk-sharing agreements (RSAs) have been implemented in many countries as a value-based payment mechanism to manage the uncertainty associated with expensive technologies. This study aimed to investigate stakeholder perspectives on value-based payment in the Singaporean context, providing insights for future directions in health technology assessment and financing.

METHODS

This descriptive qualitative inquiry involved participant interviews conducted between October 2021 and April 2022. Thematic analysis was conducted in two phases to analyze the interview transcripts.

RESULTS

Seventeen respondents participated in the study, and five key themes emerged from the analysis. Stakeholders viewed RSAs as moderately positive, despite limited experience with them. They emphasized the importance of clearly defining objectives and establishing transparent criteria for implementing these schemes. The current data infrastructure was identified as both a barrier and facilitator, as RSAs impose administrative burdens. To successfully implement these payment mechanisms, capacity building, and effective stakeholder engagement that fosters mutual trust and cocreation are crucial.

CONCLUSION

This study confirms previously identified barriers and facilitators to successful RSA implementation while contextualizing them within the Singaporean setting. The findings suggest that value-based payment has the potential to address uncertainty and improve access to healthcare technologies, but these barriers must be addressed for the schemes to be effective.

摘要

目的

药品成本的不断上升使得医疗保健系统需要探索创新的支付方式。风险分担协议(RSA)已在许多国家实施,作为一种基于价值的支付机制,用于管理昂贵技术相关的不确定性。本研究旨在探讨新加坡背景下基于价值的支付的利益相关者观点,为未来的卫生技术评估和融资方向提供见解。

方法

本描述性定性研究采用参与者访谈的方式,于 2021 年 10 月至 2022 年 4 月进行。采用两阶段的方法进行主题分析,以分析访谈记录。

结果

17 名受访者参与了研究,分析中出现了五个关键主题。利益相关者认为 RSA 是中等积极的,尽管他们的经验有限。他们强调了明确定义目标和为实施这些方案建立透明标准的重要性。当前的数据基础设施被认为是一个障碍和促进因素,因为 RSA 会带来行政负担。要成功实施这些支付机制,需要进行能力建设和有效的利益相关者参与,以促进相互信任和共同创造。

结论

本研究证实了先前确定的 RSA 实施成功的障碍和促进因素,同时将其置于新加坡背景下进行了情境化处理。研究结果表明,基于价值的支付有可能解决不确定性问题并改善获得医疗保健技术的机会,但必须解决这些障碍,才能使这些方案有效。